Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 58.58 as of 2026-10-04T15:48:28.274Z.
Consensus retrieved: 2026-10-04T15:48:17.548Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-04T15:48:28.274Z.
Quote observation: 2026-10-02T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcb0b84a88e8426f45f9a195c6bdf093ea4c1dabd3cd4d179362dc362f07dff0
Forward PE Ratio (58.58) = Dated Quote Price ($69.97) / Consensus Forward EPS ($1.19)
FORWARD PE RATIO
58.58
SECTOR MEDIAN · HEALTHCARE
19.60
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+198.88%
vs the sector median at left
Inspire Medical Systems, Inc.
Market Cap
$2.02B
Forward PE Ratio
58.58
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Inspire Medical Systems, Inc. (INSP) | $2.02B | 58.58 |
| Fortrea Holdings Inc. (FTRE)vs › | $1.90B | 23.78 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 5.68 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 54.40 |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 101.08 |
| NRC Health (NRC)vs › | $458.62M | 23.13 |
Trailing P/E
15.1
reported TTM EPS
Forward P/E
58.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.19 implies -74.2% EPS decline vs the reported trailing $4.62.
At the dated quote price of $69.97, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.19 | $1.15 – $1.26 | 9 | 58.6x |
| 2027-12-31 | $1.47 | $1.26 – $1.69 | 9 | 47.6x |
| 2028-12-31 | $1.94 | $0.86 – $2.98 | 5 | 36.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
